|  |
| --- |
| **Supplementary Table S2.** Fat mass and fat-free mass at baseline and 6 and 12 weeks after starting ART for patients who had body composition assessed by all three methods (ADP, BIA and D2O)  |
|  | **Baseline** | **Week 6** | **Week 12** |
|  | LNS | **LNS-VM** | **LNS** | **LNS-VM** | **LNS** | **LNS-VM** |
|  | N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | N | Mean (SD) | N | Mean (SD) |
| Fat mass (kg) |  |  |  |  |  |  |  |  |  |  |  |  |
| Total by D2O | 113 | 6.2 (2.9) | 111 | 6.3 (2.7) | 51 | 8.3 (3.5) | 40 | 9.1 (3.0) | 38 | 9.5 (4.5) | 38 | 10.2 (4.4) |
| Total by ADP | 113 | 7.4 (2.7) | 111 | 7.1 (2.9) | 51 | 8.9 (2.8) | 40 | 9.9 (3.5) | 38 | 10.3 (4.3) | 38 | 10.7 (3.9) |
| Total by BIA | 113 | 4.5 (2.8) | 111  | 4.6 (2.7) | 51 | 6.3 (3.2) | 40 | 7.3 (3.4) | 38 | 6.9 (3.9) | 38 | 8.2 (3.5) |
|  Truncal  | 113 | 2.0 (1.5) | 111 | 1.9 (1.5) | 51 | 2.7 (1.6) | 40 | 3.4 (2.0) | 38 | 3.3 (2.2) | 38 | 3.8 (2.1) |
|  Limb  | 113 | 2.7 (1.8) | 111 | 3.0 (1.8) | 51 | 3.7 (2.2) | 40 | 4.1 (2.1) | 38 | 3.8 (2.4) | 38 | 4.4 (2.2) |
|  |  |  |  |  |  |  |  |  |  |  |  |  |
| Fat-free mass (kg) |  |  |  |  |  |  |  |  |  |  |  |  |
| Total by D2O | 113 | 40.1 (5.8) | 111 | 38.9 (6.1) | 51 | 39.7 (5.2) | 40 | 40.7 (6.0) | 38 | 40.2 (5.4) | 38 | 41.0 (6.9) |
| Total by ADP | 113 | 39.3 (5.4) | 111 | 38.5 (6.2) | 51 | 39.4 (5.0) | 40 | 40.2 (5.5) | 38 | 39.8 (5.2) | 38 | 40.7 (6.1) |
| Total by BIA | 113 | 41.6 (6.1) | 111 | 40.4 (6.7) | 51 | 41.6 (6.4) | 40 | 42.3 (6.2) | 38 | 42.9 (6.0) | 38 | 42.9 (6.7) |
|  Truncal  | 113 | 22.8 (2.9) | 111 | 22.3 (3.3) | 51 | 23.1 (3.3) | 40 | 23.7 (3.0) | 38 | 23.8 (3.0) | 38 | 24.0 (3.3) |
|  Limb | 113 | 18.6 (3.3) | 111 | 17.9 (3.6) | 51 | 18.3 (3.3) | 40 | 18.5 (3.3) | 38 | 18.9 (3.2) | 38 | 18.9 (3.6) |
| ART, antiretroviral therapy; ADP, air displacement plethysmography; BIA, bioelectrical impedance; D2O, deuterium dilution method; LNS, Lipid nutritional supplement; LNS-VM, Lipid nutritional supplement with vitamins and minerals |